Core Viewpoint - The collaboration between Shandong New Hope Liuhe Amino Acid Co., Zhejiang University, and Tianjin University has successfully developed a key technology for the green synthesis of high-quality D,L-methionine, breaking the long-standing foreign monopoly in the methionine market [1][4]. Group 1: Technology Development - D,L-methionine is a critical limiting amino acid essential for animal feed, promoting growth and immune function in livestock [2]. - The production technology for methionine has been dominated by foreign companies, characterized by complex processes and high technical barriers [2]. - The research team, led by Professor Chen Zhirong, has spent nearly 15 years optimizing the traditional methods for synthesizing methionine [2][3]. Group 2: Production System - The main production methods for D,L-methionine include the hydrolysis method, which has significant environmental challenges and inefficiencies [3]. - The research team has developed a complete production technology system with independent intellectual property rights, focusing on green processes, continuous production, automation, and high-quality output [3][4]. - Key breakthroughs include the development of a full-cycle technology for efficient recycling of by-products, stabilization of product crystallization, and reduction of energy consumption [3]. Group 3: Market Impact - The company has established a production line with an annual capacity of 300,000 tons, significantly impacting the domestic methionine market [1][5]. - The price of methionine in China soared to 110 yuan per kilogram in 2014 due to supply shortages, but after the introduction of New Hope's product, it dropped to around 25 yuan by 2016, providing substantial cost savings for the livestock industry [5]. - The company aims to expand the application fields of methionine, creating new market opportunities for the industry [5][6].

Core Viewpoint - The European Commission has imposed anti-dumping duties on lysine originating from China, affecting several companies with varying rates [1][2]. Group 1: Anti-Dumping Duties - The final anti-dumping duties are set at 47.7% for Jilin Meihua Amino Acid Co., Ltd., 58.2% for Heilongjiang Eppen Biotech Co., Ltd., and 53.1% for other cooperating companies [1]. - The anti-dumping tax for other companies not specified in the investigation is also set at 58.2% [1]. - The investigation period for dumping is from January 1, 2023, to December 31, 2023, while the damage investigation period spans from January 1, 2020, to the end of the dumping investigation period [1]. Group 2: Investigation Timeline - The European Commission initiated the anti-dumping investigation on lysine from China on May 23, 2024 [2]. - An initial ruling on the anti-dumping case was made on January 14, 2025 [2].

Group 1 - The U.S. Department of Commerce announced an anti-dumping and countervailing duty investigation on imports of L-lysine from China [1] - The investigation pertains to products under the U.S. Customs code 2922.41.0090, with the tax number provided for reference only [1]

Core Viewpoint - Evonik announced plans to optimize the global production layout of MetAMINO® (DL-methionine) in the third and fourth quarters of 2025, including temporary shutdowns of production facilities in Singapore and Antwerp to enhance energy efficiency and reduce CO2 emissions [1][4]. Group 1: Production Capacity and Market Dynamics - The global methionine production capacity is projected to reach 2.35 million tons per year by 2024, with Evonik, Adisseo, and Sinochem accounting for 71% of this capacity [4]. - China's methionine production capacity is expected to reach 840,000 tons per year by the end of 2024, representing 36% of the global total, with further expansion anticipated to exceed 1.2 million tons by 2029 [5][6]. - China has transitioned from a net importer to a net exporter of methionine, with a projected consumption of 430,000 tons in 2024, including 160,000 tons imported and 410,000 tons exported, resulting in a net export of 250,000 tons [6]. Group 2: Production Methods and Innovations - Biotechnological methods for producing methionine offer advantages over chemical methods, including higher efficiency and reduced safety risks associated with toxic substances [7]. - The industrialization of biological methionine production has been slow due to low yield during fermentation processes, with only one company, HJ, successfully achieving bulk production [9]. - In China, significant advancements in L-methionine biosynthesis have been made by academic teams, leading to the development of microbial cell factories for efficient precursor synthesis [11][12].

Core Viewpoint - The company Xinghuo Technology plans to invest up to 3.3 billion RMB in a new amino acid production project in Daqing, Heilongjiang, with an expected annual revenue of approximately 3.9 billion RMB upon reaching full production capacity [1][10]. Project Information - Project Name: 450,000 tons amino acid and supporting engineering project [3] - Location: Daqing, Heilongjiang Province, covering approximately 483 acres [3] - Investment Entities: The project will be developed by the company's subsidiaries Heilongjiang Yipin Biotechnology and Heilongjiang Yipin Energy [3][4]. Project Construction Details - The project includes a new production line for 450,000 tons of amino acids, primarily producing 200,000 tons of feed-grade threonine and 250,000 tons of monosodium glutamate, along with related by-products [5]. - Supporting engineering will involve the construction of cogeneration and public service facilities to meet the project's heating and power needs [6]. Financial Overview - Total Investment: Up to 3.3 billion RMB, with approximately 2.95 billion RMB allocated for the amino acid production line and about 340 million RMB for supporting engineering [7]. - Funding Sources: The investment will be financed through a combination of the company's own funds and bank loans, each accounting for approximately 50% [8]. - Construction Timeline: The project is expected to take 22 months to complete [9]. Economic Benefits - Estimated Annual Revenue: Upon reaching full production and sales, the project is expected to generate around 3.9 billion RMB in annual sales, with a gross margin of approximately 10% [10]. - Investment Recovery: The estimated payback period for the investment is about 8.5 years, excluding the construction period [10]. Market Analysis - The demand for feed amino acids is increasing due to national policies promoting reduced soybean meal usage, alongside rising consumer demand for animal products [11]. - Monosodium glutamate, as a fundamental seasoning in the food industry, continues to see stable growth in production and consumption, particularly driven by the expanding ready-to-eat meal market [11]. 2024 Business Outlook - Projected Revenue: In 2024, the company anticipates revenues of 4.248 billion RMB from food additives, 11.734 billion RMB from feed additives, and other segments contributing smaller amounts [12]. - Profitability: Despite a slight decline in overall revenue due to falling market prices, increased sales volume is expected to mitigate some of the revenue loss, with gross and net profit margins improving [12].

Core Viewpoint - The company plans to invest up to 3.3 billion yuan in a new amino acid production project with a capacity of 450,000 tons annually, aiming to enhance its product offerings and revenue potential [1] Investment Project Details - The project will be constructed by the company's subsidiaries Heilongjiang Yipin Biological and Heilongjiang Yipin Energy [1] - The new production line will primarily focus on feed-grade threonine (200,000 tons) and monosodium glutamate (250,000 tons), along with related by-products [1] - The expected construction period for the project is 22 months [1] Financial Projections - Upon reaching full production, the project is anticipated to generate annual sales revenue of approximately 3.9 billion yuan [1] - The projected gross profit margin for the project is around 10% [1] - The total dynamic investment payback period is estimated to be about 8.5 years [1] Funding Sources - The funding for the project will be sourced from the company's own funds and bank loans, each accounting for approximately 50% of the total investment [1] - Funds will be allocated in phases according to the project's construction progress [1]

【SynBioCon】 获 悉， 4月1日，亨通股份公告，基于战略发展规划，公司全资孙公司亨通（内蒙古）生物科技有限公司 拟投资4.67亿元建设小品种 氨基酸产业基地项目（一期） （简称"投资项目"），最终投资金额以实际投资为准。 据公告，该投资项目 建设周期预计20个月，建成后，将新增11,880吨/年氨基酸生产能力（柔性生产线），其中L-色氨酸7380吨/年（折纯）、L-精 氨酸2100吨/年（折纯）、L-异亮氨酸精品2400吨/年 。上述建设周期与规模均仅为预计，建设周期具体以项目实施进展为准，建设规模最终能否达 标存在不确定性。 亨通股份表示，本次投资项目符合国家相关产业政策及公司整体战略发展规划，落实后将有利于优化公司产品结构，完善公司氨基酸产业链布局，进一 步夯实公司主业，提升公司主要产品的市场占有率，培育新的利润增长点。 报告期内，公司主要产品 色氨酸单位成本同比下降10.32%，L-色氨酸折百产量从2023年的3186.83吨提升至4036.70吨，同比增长26.67% ，生物 科技业务经营业绩显著增长。 拜克生物2024年度实现营业收入64911.71万元，同比增长9.04%；净利润1165 ...

Investment Rating - The investment rating for the company is "Buy" [1][7] Core Insights - The company reported a decline in revenue but a significant increase in net profit due to volume growth and cost reductions [2][3] - The animal nutrition amino acid segment showed stable performance with improved gross margins despite challenges in the market [4] - New projects and international expansion strategies are being actively pursued, contributing to future growth [5][6] Summary by Sections Financial Performance - In Q1 2025, the company achieved revenue of 6.269 billion yuan, a year-on-year decrease of 3.36%, while net profit attributable to shareholders was 1.019 billion yuan, up 35.52% year-on-year [2][3] - The decline in revenue was primarily due to lower sales prices of key products despite volume growth [3] Cost and Margin Analysis - The animal nutrition amino acid segment experienced a 5.65% increase in sales volume, with revenue remaining stable and gross margin improving by 7.43 percentage points to 19.65% [4] - The decrease in raw material costs, particularly corn, contributed to the improved margins [4] Project Development and International Strategy - The company invested approximately 2 billion yuan in new projects in 2024, with several projects reaching production [5] - An agreement was signed to acquire assets from a fermentation company, enhancing the company's international presence and product offerings [5][6] Earnings Forecast and Valuation - Revenue forecasts for 2025 and 2026 have been adjusted downwards to 27.739 billion yuan and 30.075 billion yuan, respectively, with net profit estimates also revised [6][7] - The projected earnings per share for 2025 is 1.10 yuan, with a price-to-earnings ratio of 10 times [7]

盈利预测与估值：我们预测公司25-27 年实现营业收入272.3、299.1、308.1 亿元，同比+8.6%、+9.8%、 +3.0%；实现归母净利润30.4、33.4、36.1 亿元，同比+10.9%、+10.0%、+8.0%，对应PE 分别为10、 9、9 倍，维持"强烈推荐"评级。 风险提示：豆粕价格大幅波动；原材料成本上涨；产品价格波动等 关税摩擦背景下公司业绩有望有益于豆粕涨价预期。中国大豆严重依赖进口，其中进口自美国大豆占比 约为21%，随着中美关税摩擦升温可能导致国内大豆价格上涨进而利多豆粕价格。同时，随着国家豆粕 减量替代工作推进，豆粕价格上涨有望加速替代进程，促进氨基酸产品需求增长。并且公司大原料副产 品业务利润跟随豆粕和玉米价格，因此豆粕价格上涨有利于公司业绩释放。 持续推进分红+回购，公司兼具防御属性。2024 年度公司计划实施现金分红和回购金额合计22.7 亿元， 占年度归属于上市公司股东净利润的比例82.84%。公司持续推进回购措施，截至2025 年3 月底，公司 通过集中竞价交易方式回购股份3571 万股，占公司总股本的1.25%，支付总额为3.52 亿元。 事件：公司发布202 ...

2025年全球脯氨酸行业市场规模约5.6亿美元 中国市 场占据重要地位[图] 共研产业研究院通过对公开信息分析、业内资深人士和相关企业高管的深度访谈，以及分析师专业性判断 和评价撰写了《2025-2031年中国脯氨酸市场调查与投资潜力分析报告》。本报告为脯氨酸企业决策人及投 资者提供了重要参考依据。 为确保脯氨酸行业数据精准性以及内容的可参考价值，共研产业研究院团队通过上市公司年报、厂家调 研、经销商座谈、专家验证等多渠道开展数据采集工作，并运用共研自主建立的产业分析模型，结合市 场、行业和厂商进行深度剖析，能够反映当前市场现状、热点、动态及未来趋势，使从业者能够从多种维 度、多个侧面综合了解当前脯氨酸行业的发展态势。 脯氨酸是一种环状的亚氨基酸，它是蛋白质的组成成分之一，也是哺乳动物的非必需氨基酸和生糖氨基 酸。脯氨酸作为一种重要的氨基酸，在生物体内具有多种生物学功能和代谢途径。它在蛋白质结构、代谢 调节以及疾病治疗等方面都发挥着重要作用。 脯氨酸生物功能 | 脯氨酸在肽链中有 | 它可以作为蛋白质 | 脯氨酸生物功能 脯氨酸可以通过脯 氨酸羟化酶的作用 | 脯氨酸还可以作为 | | | --- | --- ...